Comparative effectiveness research and demonstrating clinical utility for molecular diagnostic tests

Clinical Chemistry

Volumn 61, Issue 1, 2015, Pages 142-144

  Deverka, Patricia A ^a   Haga, Susanne B ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL DECISION MAKING; COMPARATIVE EFFECTIVENESS; DIAGNOSTIC TEST; EVIDENCE BASED PRACTICE; GENETIC SCREENING; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; KARYOTYPING; LABORATORY DIAGNOSIS; MEDICAL PRACTICE; MOLECULAR DIAGNOSIS; NEXT GENERATION SEQUENCING; NOTE; PERSONALIZED MEDICINE; PRIMARY MEDICAL CARE; PUBLIC-PRIVATE PARTNERSHIP; RANDOMIZED CONTROLLED TRIAL (TOPIC); REIMBURSEMENT; CLINICAL TRIAL (TOPIC); COST BENEFIT ANALYSIS; ECONOMICS; PROCEDURES; TRENDS;

CLINICAL TRIALS AS TOPIC; COMPARATIVE EFFECTIVENESS RESEARCH; COST-BENEFIT ANALYSIS; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR DIAGNOSTIC TECHNIQUES;

EID: 84920528180     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2014.223412     Document Type: Note

References (16)

1. ACMG (American College of Medical Genetics and Genomics). Molecular Pathology Rate-Setting Guide for Laboratories. Bethesda (MD); 2013. https://www.acmg.net/docs/ACMG-2013-Molecular-Pathology-Rate-Setting-Guide.pdf (Accessed May 2014).
2. UnitedHealth. Personalized medicine: trends and prospects for the new science of genetic testing and molecular diagnostics. UnitedHealth, Center for Health Reform and Modernization; 2012. http://www.unitedhealthgroup.com/-/media/UHG/PDF/2012/UNH-Working-Paper-7.ashx (Accessed July 2014).
3. Meckley LM, Neumann PJ. Personalized medicine: factors influencing reimbursement. Health Policy 2010; 94:91-100.
4. Graf MD, Needham DF, Teed N, Brown T. Genetic testing insurance coverage trends: a review of publicly available policies from the largest US payers. Pers Med 2013;10:235-43.
5. Tuckson RV, Newcomer L, De Sa JM. Accessing genomic medicine: affordability, diffusion, and disparities. JAMA 2013;309:1469-70.
6. Ginsburg GS, Kuderer NM. Comparative effectiveness research, genomics-enabled personalized medicine, and rapid learning health care: a common bond. J Clin Oncol 2012;30:4233-42.
7. Khoury MJ, Rich EC, Randhawa G, Teutsch SM, Niederhuber J. Comparative effectiveness research and genomic medicine: an evolving partnership for 21st century medicine. Genet Med 2009;11:707-11.
8. Fleurence RL, Curtis LH, Califf RM, Platt R, Selby JV, Brown JS. Launching PCORnet, a national patientcentered clinical research network. J Am Med Inform Assoc 2014;21:578-82.
9. Schully SD, Lam TK, Dotson WD, Chang CQ, Aronson N, Birkeland ML, et al. Evidence synthesis and guideline development in genomic medicine: current status and future prospects. Genet Med [Epub ahead of print 2014 Jun 19].
10. Berger AC, Olson; Roundtable on Translating Genomic-Based Research for Health; Board on Health Sciences Policy (HSP); Institute of Medicine (IOM); Center for Medical Technology Policy. Genome-based diagnostics: demonstrating clinical utility in oncology: workshop summary. Washington (DC): National Academies Press; 2013.
11. Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. New Engl J Med 2013; 369:2283-93.
12. Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, et al. A randomized trial of genotype-guided dosing of warfarin. New Engl J Med 2013;369:2294-303.
13. Mega JL, Giugliano RP. Genotype-guided dosing of warfarin. Clin Chem 2014;60:920-2.
14. Evaluation of Genomic Applications in Practice and Prevention Working Group. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 2009;11:35-41.
15. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34.
16. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. New Engl J Med 2008;359:1757-65.